Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass

Umeå University

Status: Completed

Conditions: Cardiopulmonary Bypass; Bleeding Disorder; Platelet Disorder; Platelet Dysfunction Due to Drugs

Treatments: Procedure: CPB Low Dose; Procedure: CPB High Dose

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02979158

DAPTUMU-123

Details and patient eligibility

About

Patients admitted for coronary artery bypass surgery taking antiplatelet medicine have an increased risk for bleeding.

Present study aims to compare the platelet function in two patient groups using different types of heart-lung machine methods.

It is assumed that one of the methods is superior verified by sensitive methods of testing platelet function.

Full description

Taking antiplatelet medication before cardiac surgery increases the risk for bleeding.

The surgical procedure and the use of a heart-lung machine may disturb the function of platelets, why measures to protect the existing function of platelets are of prime concern.

The present study aims to compare how two types of heart-lung machine methods influence platelet function in two groups of patients.

The platelet function will be tested before, during and after surgery by the use of two independent methods.

Enrollment: 60 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients accepted for coronary bypass surgery with dual preoperative antiplatelet therapy suspended less than 4 days prior to surgery

Exclusion criteria

• Abnormal coagulation verified from preoperative assessments, platelet count <100 000, Warfarin medication and renal insufficiency (GFR < 60 ml/min)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

60 participants in 2 patient groups

CPB Low Dose

Experimental group

Description:

Conduct of cardiopulmonary bypass using a low heparin dose verified by the activated clotting time at 250 s

Treatment:

Procedure: CPB Low Dose

CPB High Dose

Experimental group

Description:

Conduct of cardiopulmonary bypass using a high heparin dose verified by the activated clotting time at 480 s

Treatment:

Procedure: CPB High Dose